EN DE
Watch ACRO Biomedical Co., Ltd. for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

ACRO Biomedical Co., Ltd. (6748) fair value: what the stock is really worth

As of Nov 20, 2026: fair value (intrinsic value) of ACRO Biomedical Co., Ltd. stock NT$79.24, price NT$150.50, that is 47.3% below the price, quality 24 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently applies, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TW · ISIN TW0006748007

AB ACRO Biomedical Co., Ltd. logo Thin data Nov 21, 2026

ACRO Biomedical Co., Ltd.

6748 · TWO

Far too expensive (fair value 47% below the price) and weak company.

Follow free in the weekly email
Revenue last quarter +109% vs. a year ago. 
Expensive Growth (revenue 5y +16.2 %/yr in TWD) 
Fair value NT$79.24 · Strongly overvalued 
Quality 24/100 
Loss-making · -149.3% net margin (TTM) 
Negative free cash flow 
Trails peers (3/8) 
Narrow moat 10/100 · thin data
Thin data 
Estimate
Watch ACRO Biomedical Co., Ltd. for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

NT$295.50 NT$59.80 Fair Value NT$79.24 Dec 2025 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 21, 2026.

How to read this chart

12‑month range NT$59.80 – NT$295.50 · fair‑value band NT$59.43 – NT$99.05 · the NT$150.50 price screens above the NT$79.24 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 21, 2026.

Follow ACRO Biomedical Co. in your weekly email

Every Wednesday you see whether ACRO Biomedical Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

ACRO Biomedical Co., Ltd. develops medical-grade regenerative biomaterials. The company offers products in the areas of wound care, orthopedics, dentistry, ophthalmology, cosmetic micro plastic surgery, beauty and eye care, and tissue engineering and regenerative medicines.

Show moreShow less

The company was founded in 2014 and is based in Kaohsiung, Taiwan.

Stock analysis

ACRO Biomedical Co., Ltd. (6748) currently trades at NT$150.50, while our estimate is NT$79.24, 47% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently applies to this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: NT$59.43 (bear) to NT$99.05 (bull), the price of NT$150.50 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 24/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

ACRO Biomedical Co., Ltd. reported revenue of 38.3M TWD in FY2025 versus 21.8M TWD in FY2021, a compound +15.1%/yr. Reported net income was −82.7M TWD in FY2025.

Key figures

Market cap 12.8B TWD (≈ $387M) Small · EPS (TTM) NT$-1.20 · Net margin −149% · Return on equity −9.6% · Return on assets (EBIT) −15.3% (5-year average) · Operating margin −178% · Revenue (TTM) 52.8M TWD · Revenue growth (quarter YoY) +109%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 49% below its 52-week high and 152% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −4% fair-value upside, at −47%, 6748 screens richer than that median.

Fair Value

Bear NT$59.43 Fair Value NT$79.24 Bull NT$99.05
Price NT$150.50 · Downside -47.3%
Estimate. None of our valuation models currently applies to this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 24/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 21
Are margins and returns getting better?
Cashflow 2
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 65
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 69
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 32/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−13.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.2%
Start year 2020 (pandemic)
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−310.4% (2020) → −242.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

6748 screens overvalued: fair value 47% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare ACRO Biomedical Co., Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 854 stocks

Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 24 · Bottom 25%
Fair Value upside −47.3% · Bottom 25%
Profitability
Return on assets −7.3% · Above median
Net margin (12 months) −149.3% · Bottom 25%
Operating margin (12 months) −178.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 108.9% · Top 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 11.55× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 32
PAST (return on equity)0 · sector 0
HEALTH (low debt)–
DIVIDEND (yield)0 · sector 23

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $920.69 $1,275.02 +38% vs 6748
Vertex Pharmaceuticals Incorporated VRTX $515.02 $566.52 +10% vs 6748
Samsung Biologics Co 207940 ₩1,355,000 ₩1,490,500 +10% vs 6748
argenx SE ARGX $925.70 $908.40 −2% vs 6748
CSL Limited CSL A$197.29 A$188.80 −4% vs 6748
BeOne Medicines AG 6160 HK$230.80 HK$152.92 −34% vs 6748
Moderna, Inc MRNA $195.00 $119.97 −38% vs 6748
Revolution Medicines, Inc RVMD $161.20 $83.14 −48% vs 6748
Celltrion, Inc 068270 ₩213,000 ₩74,574 −65% vs 6748
Royalty Pharma plc RPRX $68.45 $19.01 −72% vs 6748

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

ACRO Biomedical Co., Ltd.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "ACRO Biomedical Co., Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/6748

Frequently asked questions

Is ACRO Biomedical Co., Ltd. (6748) overvalued or undervalued?
As of Nov 21, 2026, our estimate of fair value is NT$79.24 versus a price of NT$150.50, about 47% lower (overvalued).
What is the fair value of 6748?
Our estimate for ACRO Biomedical Co., Ltd. is NT$79.24 (as of Nov 21, 2026), built from audited fundamentals. The current price: NT$150.50.
What is the quality score of 6748?
ACRO Biomedical Co., Ltd. has a Quality Score of 24/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ACRO Biomedical Co., Ltd. (6748)?
We do not set a price target; the yardstick is our estimate of NT$79.24 (as of Nov 21, 2026). Cautious scenario NT$59.43, optimistic scenario NT$99.05. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently applies, not an analyst target.
What is the ACRO Biomedical Co., Ltd. stock forecast for 2026?
Our estimate puts fair value at NT$79.24, about 47% lower versus a price of NT$150.50 (overvalued). Cautious scenario NT$59.43, optimistic scenario NT$99.05. The calculation is refreshed regularly with new filings.
What is the revenue of ACRO Biomedical Co., Ltd. (6748)?
ACRO Biomedical Co., Ltd. reported trailing-twelve-month revenue of about 52.8M TWD (latest available figure, as of Nov 21, 2026).
What is the intrinsic value of ACRO Biomedical Co., Ltd. (6748)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ACRO Biomedical Co., Ltd. it is NT$79.24 per share (as of Nov 21, 2026), against a price of NT$150.50.
Is ACRO Biomedical Co., Ltd. stock overvalued or undervalued in 2026?
As of Nov 21, 2026, 6748 trades above its calculated fair value: price NT$150.50, fair value NT$79.24, a gap of about −47% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6748?
No. The price is what the market pays today (NT$150.50); the fair value is what the company's own numbers justify (NT$79.24). For ACRO Biomedical Co., Ltd. the two are NT$71.26 per share apart. That gap is exactly why we show both numbers side by side.
How much is ACRO Biomedical Co., Ltd. worth?
The market values ACRO Biomedical Co., Ltd. at about 12.8B TWD (market capitalisation, as of Nov 21, 2026). Per share that is NT$150.50; our models calculate a fair value of NT$79.24 per share.
What do the bullish and bearish scenarios say about 6748?
Our models span a range for ACRO Biomedical Co., Ltd.: cautious scenario NT$59.43, base NT$79.24, optimistic NT$99.05 per share (as of Nov 21, 2026, price NT$150.50). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of ACRO Biomedical Co., Ltd. (6748)?
Balance-sheet figures for ACRO Biomedical Co., Ltd. (as of Nov 21, 2026): return on equity −9.6%. They feed the Quality Score of 24/100, which measures business quality independently of the share price.
How far is 6748 from its 52-week high?
ACRO Biomedical Co., Ltd. trades at NT$150.50, about 49% below its 52-week high of NT$295.50 and 152% above the low of NT$59.80 (as of Nov 20, 2026). Distance from the high says nothing about value: that is what the fair value of NT$79.24 is for.
Which stocks are comparable to ACRO Biomedical Co., Ltd.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ACRO Biomedical Co., Ltd. stock attractive at the current price?
The data as of Nov 21, 2026: price NT$150.50, calculated fair value NT$79.24 (−47%), Quality Score 24/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 10.1% above its aggregate fair value. ACRO Biomedical Co., Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ACRO Biomedical Co., Ltd. (6748)?
The closing price on Nov 20, 2026 was NT$150.50. Our estimate is NT$79.24, about 47% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ACRO Biomedical Co., Ltd. right now?
The price sits above even our optimistic bull case (NT$99.05). The favourable scenario is already priced in. Weak quality (24/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of ACRO Biomedical Co., Ltd.

How large is the market capitalisation of ACRO Biomedical Co., Ltd. (6748)?
The market capitalisation of ACRO Biomedical Co., Ltd. is 12.8B TWD (≈ $387M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of ACRO Biomedical Co., Ltd. (6748)?
Earnings per share at ACRO Biomedical Co., Ltd. are NT$-1.20. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of ACRO Biomedical Co., Ltd. (6748)?
The net margin of ACRO Biomedical Co., Ltd. is −149% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of ACRO Biomedical Co., Ltd. (6748)?
The return on equity (ROE) of ACRO Biomedical Co., Ltd. is −9.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ACRO Biomedical Co., Ltd. (6748)?
On an EBIT basis the return on assets of ACRO Biomedical Co., Ltd. is −15.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ACRO Biomedical Co., Ltd. (6748)?
The operating margin of ACRO Biomedical Co., Ltd. is −178% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ACRO Biomedical Co., Ltd. (6748)?
Revenue at ACRO Biomedical Co., Ltd. is growing 109% in the last quarter versus the same quarter a year earlier (3y avg +11.5%). How much revenue grew in the last quarter versus the same quarter a year earlier (YoY). The 3-year average next to it puts the single quarter in context.
How much free cash flow does ACRO Biomedical Co., Ltd. (6748) generate?
The free cash flow of ACRO Biomedical Co., Ltd. is −63.0M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does ACRO Biomedical Co., Ltd. (6748) hold?
ACRO Biomedical Co., Ltd. holds more cash than debt, 176M TWD net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch ACRO Biomedical Co., Ltd. in the live analysis

One click puts ACRO Biomedical Co., Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.